|
Target/therapies for chronic recurrent erythema nodosum leprosum
Pugazhenthan Thangaraju1, Shoban Babu Varthya2, Sajitha Venkatesan1
1 Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India
2 Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
Correspondence Address:
Dr. Pugazhenthan Thangaraju
Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh
India
A Type 2 lepra reaction or erythema nodosum leprosum is an anticipated complication in the lepromatous spectrum of leprosy cases. It is an example of an immune complex-mediated complement activated disease (Type III hypersensitivity reaction). Hence, we tried to target the inflammatory mediators and the mental stressors for the possible management strategies.
How to cite this article:
Thangaraju P, Varthya SB, Venkatesan S. Target/therapies for chronic recurrent erythema nodosum leprosum.Indian J Pharmacol 2020;52:222-226
|
How to cite this URL:
Thangaraju P, Varthya SB, Venkatesan S. Target/therapies for chronic recurrent erythema nodosum leprosum. Indian J Pharmacol [serial online] 2020 [cited 2022 Jun 27 ];52:222-226
Available from: https://www.ijp-online.com/article.asp?issn=0253-7613;year=2020;volume=52;issue=3;spage=222;epage=226;aulast=Thangaraju;type=0 |
|
